| scholarly article | Q13442814 |
| P2093 | author name string | G B Baretton | |
| U Sommer | |||
| D E Aust | |||
| P2860 | cites work | BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status | Q21245742 |
| Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review | Q24289005 | ||
| Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer | Q24614511 | ||
| KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. | Q27824867 | ||
| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer | Q27851456 | ||
| PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies | Q27851465 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab | Q27851587 | ||
| A genetic model for colorectal tumorigenesis | Q27860582 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 | ||
| 5-Fluorouracil: mechanisms of action and clinical strategies | Q28201937 | ||
| Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 | ||
| Genetic alterations during colorectal-tumor development | Q28281200 | ||
| Systematic review of microsatellite instability and colorectal cancer prognosis | Q28303189 | ||
| Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer | Q28305293 | ||
| Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer | Q28308193 | ||
| Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study | Q28348036 | ||
| Molecular predictors of survival after adjuvant chemotherapy for colon cancer | Q28363159 | ||
| KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment | Q28741021 | ||
| Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study | Q29619653 | ||
| Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer | Q33586020 | ||
| DNA mismatch repair and cancer | Q34164892 | ||
| A review of excision repair cross-complementation group 1 in colorectal cancer. | Q34209365 | ||
| Defective mismatch-repair colorectal cancer: clinicopathologic characteristics and usefulness of immunohistochemical analysis for diagnosis. | Q34550752 | ||
| The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment | Q34560951 | ||
| Colorectal serrated adenocarcinoma | Q34597935 | ||
| BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer | Q34621860 | ||
| Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. | Q34624122 | ||
| Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. | Q34654711 | ||
| Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma. | Q35024163 | ||
| External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds | Q35584550 | ||
| Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications | Q35836592 | ||
| PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. | Q35953893 | ||
| Epidermal growth factor receptor targeting in cancer | Q36557269 | ||
| The epidermal growth factor receptor pathway: a model for targeted therapy | Q36603677 | ||
| The validity of the Royal College of Pathologists' colorectal cancer minimum dataset within a population | Q36610625 | ||
| Classification of colorectal cancer based on correlation of clinical, morphological and molecular features | Q36699559 | ||
| PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer | Q37137091 | ||
| Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. | Q37157691 | ||
| Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer | Q37287501 | ||
| KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. | Q37330719 | ||
| What can the molecular pathologist offer for optimal decision making? | Q37799917 | ||
| Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? | Q37815613 | ||
| Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer | Q37826269 | ||
| Molecular predictors of response to chemotherapy in colorectal cancer | Q37856121 | ||
| Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. | Q38934630 | ||
| Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer | Q39813785 | ||
| Recurrent KRAS codon 146 mutations in human colorectal cancer | Q40232898 | ||
| BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? | Q42947711 | ||
| KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial | Q43250046 | ||
| Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial | Q43254499 | ||
| Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial | Q43290037 | ||
| Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis | Q43723138 | ||
| UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity | Q43979778 | ||
| A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer | Q44093928 | ||
| Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group | Q45273769 | ||
| Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer | Q45837382 | ||
| Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice. | Q45938898 | ||
| PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. | Q46034442 | ||
| Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study | Q46465639 | ||
| Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial | Q46570394 | ||
| Microsatellite instability and colorectal cancer prognosis. | Q46831092 | ||
| Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. | Q50888998 | ||
| Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. | Q51502354 | ||
| Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. | Q51916596 | ||
| Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. | Q52846071 | ||
| Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. | Q54081321 | ||
| PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis. | Q54568696 | ||
| Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified | Q56589468 | ||
| Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer | Q56601042 | ||
| P921 | main subject | decision making | Q1331926 |
| P304 | page(s) | x63-70 | |
| P577 | publication date | 2012-09-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | What can molecular pathology offer for optimal decision making? | |
| P478 | volume | 23 Suppl 10 |
Search more.